Core Viewpoint - Trinity Biotech plc has entered into agreements with Perceptive Advisors to enhance its financial flexibility and optimize its capital structure, supporting ongoing and future growth projects [1][2]. Financial Capacity and Operational Flexibility - The transactions strengthen Trinity Biotech's financial capacity and operational flexibility, enabling continued investment in strategic growth priorities and reinforcing its ability to deliver advanced diagnostic and diabetes management solutions [2][3]. - The agreements position Trinity Biotech to advance its long-term growth agenda while supporting a reduction in overall debt levels [2]. Overview of the Transactions - The agreements reflect a positive relationship between Trinity Biotech and Perceptive Advisors, underscoring their support for the Company's strategy and operational momentum [3]. Financial Summary - The Second Amendment to the Credit Agreement extends the maturity to early 2027 and provides increased near-term funding [6]. - New term-loan proceeds of $5 million will strengthen liquidity for key strategic development initiatives, including the continuous glucose monitoring solution, CGM+ [7]. - Up to $60 million in elective equitization capacity under the term-loan may allow for significant debt and cash interest cost reductions [7]. - Equity settlement mechanisms for milestone payments and contingent obligations are designed to reduce cash requirements [7]. Management Commentary - The CEO of Trinity Biotech stated that these developments place the company in a stronger strategic position to accelerate its innovation agenda, particularly in diabetes management and diagnostics [8].

Financial Performance - Revenue for Q2 2025 was $10.8 million, a decrease compared to $15.8 million in Q2 2024[4, 7] - Like-for-like revenue (excluding sub-scale lower-margin third-party product lines) was $10.7 million in Q2 2025, versus $15.0 million in Q2 2024[7] - Gross profit was $4.6 million in Q2 2025, down from $5.7 million in Q2 2024[7] - Gross margin improved to 42.6% in Q2 2025, compared to 36.2% in Q2 2024[7] - Net loss was $6.0 million in Q2 2025, an improvement from $6.8 million in Q2 2024[4] - Basic and diluted loss per ADS was $0.32 in Q2 2025, compared to $0.71 in Q2 2024[4] - Adjusted EBITDA was negative $2.1 million in Q2 2025, compared to negative $1.4 million in Q2 2024[4] Expenses and Liquidity - R&D expense was $0.6 million in Q2 2025, compared to $0.9 million in Q2 2024, with $1.7 million capitalized[10] - SG&A expense was $7.0 million in Q2 2025, up from $6.4 million in Q2 2024, driven by foreign exchange loss and corporate finance activities[10] - Restructuring costs were $0.7 million in Q2 2025, compared to $1.9 million in Q2 2024[10] - Cash balance at the end of Q2 2025 was $1.5 million, down from $5.3 million in Q2 2024[10]

Core Insights - Trinity Biotech has received a significant order for 9 million units of its TrinScreen HIV screening product, indicating a recovery in the global HIV testing market [1][2][4] - The company achieved positive Adjusted EBITDA in Q3 2025 and anticipates further profitability growth in Q1 and Q2 2026 through its Comprehensive Transformation Plan [1][8][10] TrinScreen HIV Order - The order reflects renewed commitment from global health organizations to support HIV screening, particularly in heavily affected regions [2] - TrinScreen HIV is a WHO-prequalified rapid diagnostic test designed for high-volume screening, providing reliable results in various clinical settings [2] Manufacturing and Supply Chain - Trinity Biotech will produce the tests through a WHO-approved outsourced manufacturing process, allowing for efficient scalability [3] - The company expects to fulfill the order in Q4 2025 and Q1 2026, adjusting its manufacturing and supply chain to meet increased demand [3] Financial Performance - Revenues for Q3 2025 increased by 32% to $14.3 million compared to $10.8 million in Q2 2025, driven by a $2.1 million increase in rapid HIV test sales and a rise in haemoglobin product sales [8] - Gross profit for Q3 2025 was $6.5 million, with an increase in gross margin from 42.6% to 45.2% due to operational changes [8] - Adjusted EBITDA for Q3 2025 was $0.5 million, a significant improvement from negative $2.1 million in Q2 2025 [8] Strategic Positioning - The order is expected to positively impact revenue and profitability, highlighting the company's strategic position in the global infectious disease diagnostics market [4] - The company is focused on immediate growth opportunities and expanding into international markets with new product offerings [7][14] Management Transition - Susan O'Connor has completed her term as interim Chief Financial Officer, with Paul Murphy promoted to the role [10]

Core Insights - Trinity Biotech is advancing its mission to deliver next-generation diabetes management solutions and expand its global market penetration, particularly in the $2 billion+ HbA1c market [1][2] Company Developments - Trinity Biotech has secured regulatory clearances in multiple countries for its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer, which is now available in over 10 countries, including the United States [1] - The upgraded column system enhances testing throughput by up to four times compared to the existing system, reduces instrument downtime, and minimizes maintenance requirements, leading to improved operational efficiency [3][7] - The Premier Hb9210 solution is recognized as a gold standard in HbA1c testing, with strong clinical performance confirmed by peer-reviewed studies [3] Market Potential - The global laboratory HbA1c market is currently valued at over $2 billion and is projected to exceed $3.5 billion by 2030, driven by the increasing prevalence of diabetes [2] - The launch of the advanced system in key markets positions Trinity Biotech to capture further growth opportunities in the global diabetes care segment [3] Operational Efficiency - The new column system's operational gains create a more efficient workflow for clinical laboratories, supporting broader adoption of the platform [3] - The latest software update enhances automation of routine tasks, enabling greater productivity and cost savings [7]

Core Insights - Trinity Biotech has received WHO approval for offshored and outsourced upstream manufacturing of its Uni-Gold™ HIV rapid test, marking a significant milestone in its transformation plan aimed at sustainable profitability [1][7] - The transition to an outsourced manufacturing model is expected to enhance gross margins, EBITDA, and cash flow generation, while maintaining product integrity and regulatory compliance [2][5] Company Strategy - The initiative is part of a complex project developed over two years, showcasing the leadership's capability to execute strategic business transformations for long-term capital value [3] - The company aims to streamline operations, reduce fixed costs, and focus on innovation and market expansion through strategic partnerships with world-class manufacturing providers [4][5] Financial Impact - The expected improvements in gross margin, EBITDA, and cash flow generation are central to the company's profitability-focused transformation strategy [5][7]

Core Insights - Trinity Biotech plc has announced a strategic collaboration with a leading bioinformatics company to enhance the analysis of clinical trial data for its EpiCapture test, a PCR-based epigenetic liquid biopsy for monitoring prostate cancer progression [1][3] - The EpiCapture test offers a non-invasive method to detect DNA methylation patterns associated with high-grade prostate cancer, aiming to improve patient care by reducing unnecessary invasive procedures [2][5] - Prostate cancer represents a significant clinical and economic burden, with approximately 1 in 8 men diagnosed in the U.S. and annual costs for diagnosis and treatment exceeding $10 billion [4] Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [9] - The company develops and markets diagnostic systems for point-of-care and clinical laboratory segments, recently entering the wearable biosensor market through the acquisition of Waveform Technologies Inc. [9] - Trinity Biotech's products are utilized to detect infectious diseases and quantify various chemistry parameters in blood samples, with a distribution network spanning over 75 countries [9] Clinical Development - The collaboration aims to support the late-stage development of the EpiCapture test, preparing it for regulatory approval and commercialization [3][7] - A study published in The Journal of Clinical Oncology – Precision Oncology indicated that EpiCapture accurately predicted all high-grade cancers when used with the PSA test, highlighting its potential to enhance clinical decision-making [6]

Core Viewpoint - Trinity Biotech plc is welcoming a proposal from its largest investor, Perceptive Advisors, to convert a portion of its outstanding debt into equity, which is seen as a strategic initiative to strengthen the company's balance sheet and enhance financial flexibility [1][2]. Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [5]. - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, with recent expansion into the wearable biosensor industry through the acquisition of Waveform Technologies Inc. [5]. - Products include diagnostics for infectious diseases and quantification of Haemoglobin A1c and other chemistry parameters in various blood samples [5]. Investor Relations - Perceptive Advisors, a leading life sciences investment firm with approximately $8 billion in assets, has been a supportive partner during Trinity Biotech's transformation [2][7]. - The proposed equitization program aims to align the interests of all stakeholders, including shareholders, and is expected to facilitate discussions that are mutually beneficial [3][2].

Exhibit 99.2 Execution Version First Amendment to Sixth Amended and Restated Credit Agreement and Guaranty This First Amendment to Sixth Amended and Restated Credit Agreement and Guaranty (herein, this "Agreement") is entered into as of October 16, 2025 (the "First Amendment"), by and among TRINITY BIOTECH, INC., a Delaware corporation ("U.S. Holdings"), CLARK LABORATORIES, INC. (d/b/a Trinity Biotech (USA)), a New York corporation ("U.S. Clark"), BIOPOOL U.S., INC., a Delaware corporation (d/b/a Trinity Bi ...

Company Overview - Trinity Biotech plc is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [5][6] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments [5][6] Recent Developments - The company announced the appointment of Paul Tivnan as a Non-Executive Director on its Board of Directors [1] - Mr. Tivnan has over 25 years of senior leadership experience in finance, capital markets, and corporate governance across various sectors, including infrastructure and cleantech [2][3] - His previous roles include CFO of Deriva Energy LLC and CFO of Brookfield Renewable Ireland, where he led a successful IPO [2][3] Strategic Goals - The appointment of Mr. Tivnan is aimed at strengthening corporate governance and bringing diverse perspectives to the Board as the company pursues growth opportunities in diagnostics and wearable health technologies [3] - Trinity Biotech is focused on executing its transformation strategy and developing a range of biosensor devices, starting with a continuous glucose monitoring product [6]

Core Insights - Trinity Biotech has received regulatory approval to initiate offshore and outsourced manufacturing of its TrinScreen™ HIV rapid test, marking a significant step in its transformation strategy [1][2][3] - The transition to an outsourced production model is expected to drive gross margin expansion, free up working capital, and reduce fixed costs, thereby supporting the company's broader profitability and growth objectives [1][4] Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [5] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry [5]